<code id='A905DE6D30'></code><style id='A905DE6D30'></style>
    • <acronym id='A905DE6D30'></acronym>
      <center id='A905DE6D30'><center id='A905DE6D30'><tfoot id='A905DE6D30'></tfoot></center><abbr id='A905DE6D30'><dir id='A905DE6D30'><tfoot id='A905DE6D30'></tfoot><noframes id='A905DE6D30'>

    • <optgroup id='A905DE6D30'><strike id='A905DE6D30'><sup id='A905DE6D30'></sup></strike><code id='A905DE6D30'></code></optgroup>
        1. <b id='A905DE6D30'><label id='A905DE6D30'><select id='A905DE6D30'><dt id='A905DE6D30'><span id='A905DE6D30'></span></dt></select></label></b><u id='A905DE6D30'></u>
          <i id='A905DE6D30'><strike id='A905DE6D30'><tt id='A905DE6D30'><pre id='A905DE6D30'></pre></tt></strike></i>

          Home / comprehensive / entertainment

          entertainment


          entertainment

          author:comprehensive    Page View:34448
          David L. Ryan/Boston Globe

          A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical institute in Cambridge’s Kendall Square with $500 million in private funding with the aim of shortening the path from research breakthroughs to life-saving medicines.

          The institute, called Arena BioWorks, will put drug discovery and company creation under one roof, upending the traditional model where academic research and venture-backed drug development are separate.

          advertisement

          Backed by deep-pocketed investors including Steve Pagliuca, the former co-chair of Bain Capital and Celtics co-owner, and high-tech mogul Michael Dell, Arena has already lured top scientists from academic labs with lucrative compensation packages, but so far has publicly named only a few.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In